论文部分内容阅读
目的:探讨金属硫蛋白(Metallothionein,MT)在乳腺癌中过表达的意义及其与乳腺癌化疗方案选择的相关性。方法:利用SP免疫组织化学技术,检测88例乳腺癌组织中MT表达率。结果:MT在乳腺癌中总阳性率为67.05%(59/88)。MT在髓样癌、小叶癌和导管癌中的阳性率分别为41.67%,85.71%和62.50%。在浸润型乳腺癌组阳性率明显高于非浸润型癌组(P<0.05);在小叶癌组阳性率高于髓样癌组和导管癌组(P<0.05);淋巴结转移组阳性率高于非转移组(P<0.05)。结论:MT表达与乳腺癌的病理类型及有否淋巴结转移相关,检测MT对乳腺癌化疗方案的制定有指导意义。
Objective: To investigate the significance of Metallothionein (MT) overexpression in breast cancer and its correlation with chemotherapy regimens in breast cancer. Methods: SP immunohistochemistry was used to detect the expression of MT in 88 cases of breast cancer. Results: The total positive rate of MT in breast cancer was 67.05% (59/88). The positive rates of MT in medullary carcinoma, lobular carcinoma and ductal carcinoma were 41.67%, 85.71% and 62.50% respectively. The positive rate in invasive breast cancer group was significantly higher than that in non-invasive cancer group (P <0.05); the positive rate in lobular cancer group was higher than that in medullary carcinoma group and ductal carcinoma group (P <0.05); the positive rate in lymph node metastasis group was high In non-metastatic group (P <0.05). Conclusion: The expression of MT is correlated with the pathological type and lymph node metastasis of breast cancer. Detecting MT may be helpful for the development of breast cancer chemotherapy regimen.